Life Science Nation Newsletter | May 3, 2018 | Issue 264

  The LSN Story   |   Investor Platform   |   Company Platform   |   RESI Conference   |   Fundraising Consulting
RESI Boston Innovation Challenge
Life Science Investor Mandates (Apr. 25 - May 2 )
Looking to Invest in Seed-Stage Medtech, Diagnostics, and Digital Health Companies
Looking to Invest Up to $10M or More in Life Science Companies in North America
Seeks to Invest in All Sectors of Life Sciences, with Focus on Companies Outside of Major Biotech Hubs
Invests in Digital Health, with Increased Interests in Investment Opportunities in Biotech Therapeutics
Nature BioEntrepreneur Features LSN: Aligning Needs
LSN Services
LSN's Sourcing & Ranking Service (SRS) provides clients with an opportunity to quickly source, vet, rank and engage with partners that are licensing global technology assets.

Click to see investors that are a fit for your product and stage of development

Click here if you are a service provider and want to see a list of funded life science companies that are a fit for you

Click here if you want to receive free, targeted early stage dealflow for your life science investment firm

Free Copy of LSN's Book

LSN Videos
By Dennis Ford, Founder & CEO, Life Science Nation; Creator of RESI Conference Series

To raise capital, an early-stage CEO is going to need to create a Global Target List of potential investors as one of the first things they do. With a vetted list of investors who are a fit, the fundraising executive has to make a concerted effort to reach out to all the parties on the list. This means reach out to them, book meetings and do a lot of follow up to move the dialogue along. While many CEOs might be tempted to look for an outside service to do all this work for them, my recommendation is to do it yourself if possible.

A fundraising campaign is eminently something your company can get done internally if you hire a staff person (an admin, a college intern, or a business professional who likes making calls) to phone and email investors, set up meetings, and organize the campaign follow up. In a typical case, there are around 400 relevant global early stage investors across 10 categories of investor. If you come to RESI on June 4th, you might find 20-30% of these target investment firms are attending. By using RESI Partnering effectively, you might be able to have a one-on-one meeting with 12-15 of these investors, and maybe catch ad hoc meetings with a further 5. Additionally, the RESI innovation Challenge is a fabulous vehicle to create dialogue with the investor and channel partners to whom you need to be talking.

If you read my book The Life Science Executive's Fundraising Manifesto, you will see that I am a big proponent of getting all the potential global investors rounded up in a Global Target List and then working the whole list. Establish a dialogue, go to RESI or other events and meet them, email all the targets regularly with news on your company and how it is reaching milestones and getting compelling data. If you market to this list in an adroit and cogent way you will get on the investors' radar screen. This is how I recommend marketing and socializing your company to your target audience. It's a numbers game, and when you market to your Global Target List consistently you never know who will surface. But if you are just sending out material to investors who are attending an event, why not send out to all who are a potential fit for you? It only takes one investor whose interest you have garnered to move a deal along.

Steven ten Holder
An interview with
Steven ten Holder,
COO, Acorn Biolabs

- By  Greg Mannix
VP of International BD, LSN
Greg Mannix

This year's 2nd place finisher at the Innovation Challenge at RESI on MaRS was Acorn Biolabs. LSN interviewed COO, Steven ten Holder and got some key takeaways on how Acorn used the RESI Innovation Challenge effectively:
  • The Acorn team used their design and marketing skills to attract attention, rather than focusing purely on presenting scientific data
  • The team used the Innovation Challenge to create ad hoc meetings with 40 investors
  • Acorn is working to build on their success with press releases and investor follow-up after the event.
Acorn Biolabs is a Toronto-based company working out of the actual MaRS facility that has developed a novel non-invasive at-home kit to collect and viably transport cells and cryopreserve these cells as a way to ensure people will always have access to their own young therapeutically-capable cells...

By By Jessica Yang, Investor Research Analyst, LSN

During RESI on MaRS - as part of Toronto Health Innovation Week - we invited five panelists from renowned investment groups focusing on genomics to share their insights. How do they assess the genomics-related areas of investment?

- Moderated by  Ihor Boszko, Vice President, Business Development, Ontario Genomics, the Genomics Investor Panelists were: 
  • Dion Madsen, Senior Managing Partner, Healthcare Fund, BDC Healthcare Fund 
  • Joby McKenzie, Senior Vice President, Business Development, Life Labs
  • Noel Jee, Investment Associate, Illumina Ventures
  • Wei Tao, Member, Sand Hill Angels

Here are some takeaway points from the panel discussion...

Created & Produced by